A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

A Non-interventional Survey on the Epidermal Growth Factor Receptor (EGFR) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01106781

Acronym

ICAN

Enrollment

591

Registered

2010-04-20

Start date

2010-08-31

Completion date

2014-01-31

Last updated

2014-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Keywords

EGFR mutation test, NSCLC, Non-Interventional Study, EGFR mutation status

Brief summary

This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological diagnosed as adenocarcinoma type of non-small cell lung cancer * Have completed lung cancer operation * The tumour EGFR gene mutation status test was performed as regular medical practice

Exclusion criteria

* Patients who disagree to participate this study

Design outcomes

Primary

Measure	Time frame
type and prevalence of EGFR mutation	up to 3 months

Secondary

Measure	Time frame
Operation type and adjuvant treatment type	up to 3 months
Disease Free Survival rate	up to 3 months

Countries

China

Outcome results